Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lundbeck
Pharma
2024's top biopharma M&A deals
Despite a return to dealmaking grandeur in 2023, the biopharma industry’s appetite for large-scale mergers and acquisitions was notably more muted in 2024.
Fraiser Kansteiner
,
Zoey Becker
,
Angus Liu
,
Kevin Dunleavy
,
Eric Sagonowsky
Jan 13, 2025 3:00am
Lundbeck, Otsuka nab Barbara Corcoran for new agitation campaign
Sep 27, 2024 8:56am
AbbVie's Skyrizi, Rinvoq retake top TV drug ad spenders' crown
Aug 12, 2024 10:08am
With new agreement, Lundbeck leaves Trintellix to partner Takeda
Jul 31, 2024 11:41am
AbbVie's Skyrizi regains top pharma TV ad spender title
Jun 5, 2024 9:50am
Takeda, Lilly-Innovent, BIO-China—Fierce Pharma Asia
May 10, 2024 9:30am
